Relating to the cost of prescription drugs; declaring an emergency.

Requires Department of Consumer and Business Services to investigate methods for collecting information about rebates and markups used in pharmaceutical supply chain and to report to interim committees of Legislative Assembly recommendations for collecting information. Authorizes department to access, use and disclose data from all payer, all claims database under specified conditions. Modifies increase in price of prescription drug that triggers pharmaceutical manufacturer's obligation to report data under Prescription Drug Price Transparency Act. Requires prescription drug manufacturers to respond promptly to requests by department in administering Prescription Drug Price Transparency Act. ] Allows department to disclose information about consumers' notifications of increases in prices of prescription drugs but not personally identifiable information about consumers. Modifies membership of, charge to and reporting requirements for Task Force on the Fair Pricing of Prescription Drugs. Extends sunset of task force to December 31, 2022. Declares emergency, effective on passage.